NAIINasdaqMedicinal Chemicals & Botanical ProductsUS GAAP · USD

Natural Alternatives International, Inc

Natural Alternatives International, Inc. manufactures private-label nutritional supplements for brands that sell vitamins, minerals, herbs, and other health products to consumers in the U.S. and abroad. It also monetizes its beta-alanine intellectual property through CarnoSyn®, SR CarnoSyn®, and TriBsyn™ raw material sales, licensing, and royalty arrangements.

Revenue143m USD
+9.7 %y/y
Operating profit (EBIT)-18.8m USD
−116.5 %y/y
EBIT margin-13.2%
−6.5 ppy/y
Net income-20.7m USD
−52.4 %y/y
Free cash flow-12.6m USD
−644.3 %y/y

Fiscal year 2026 · change from previous year

Development 2021–2026

-50050100150200m USD2021: 179 m USD2021: EBIT 14 m USD20212022: 171 m USD2022: EBIT 14 m USD20222023: 154 m USD2023: EBIT 4.7 m USD20232024: 114 m USD2024: EBIT -8.5 m USD20242025: 130 m USD2025: EBIT -8.7 m USD20252026: 143 m USD2026: EBIT -19 m USD2026143-19
RevenueOperating profit (EBIT)

Business

Share of revenue
Private-label contract manufacturing88 %

Manufacturing of finished nutritional supplement products for third-party brands under customer specifications.

Patent and trademark licensing12 %

Licensing and royalty income tied to the company's beta-alanine intellectual property and trademarks.

Customers

The company sells primarily to private-label brands and distributors that market supplements and health products to end consumers. Management says revenue has historically depended on two or three large customers, so order timing, new product launches, and customer marketing plans can materially swing results.

Private-label supplement brands

Buy contract manufacturing for vitamins, minerals, herbs, and other nutritional supplements to sell under their own labels.

Health care product marketers

Outsource production and packaging of consumer health products where formulation quality and supply reliability matter.

Beta-alanine ingredient buyers

Purchase CarnoSyn® or TriBsyn™ raw material for sports nutrition, wellness, healthy aging, and medical foods.

Licensees and royalty partners

Use the company's patents, trademarks, and trade names in exchange for licensing and royalty payments.

Strategy

Management is focused on diversifying away from a small customer base while improving utilization of its certified facilities. It is also pushing beta-alanine commercialization through raw material sales, new distribution channels, and licensing to broaden revenue sources and reduce dependence on contract manufacturing alone.

Customer diversificationShort term

Reduces dependence on two or three large buyers and lowers order-timing volatility.

Beta-alanine commercializationMedium term

Creates higher-margin IP-linked revenue streams beyond contract manufacturing.

Operational efficiencyShort term

Better utilization and cost control can improve profitability in a low-margin manufacturing model.

Geography

Q1/2025

The company serves consumers both within and outside the U.S., but the filings provided do not disclose a country revenue split. It operates a wholly owned manufacturing subsidiary in Manno, Switzerland, which gives it a non-U.S. production footprint and exposure to cross-border supply chain, tariff, and foreign exchange effects.

United States63 %
Other countries (US filing)37 %

Share of the revenue the company reports by geography.

Risks

The biggest company-specific risk is customer concentration, since a few private-label accounts can materially affect sales and quarterly timing. The business is also exposed to tariffs, supply chain disruption, foreign exchange, and geopolitical instability, while the contract manufacturing model remains sensitive to raw material availability, customer demand, and rebate estimates.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Geopolitical instability2Tariffs and trade duties3
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Customer concentrationImpact: High

    Largest private-label customer represented 31% of total net sales in the six months ended Dec. 31, 2025.

    Exposure: A small number of customers drive a large share of revenue and order timing.

  2. Geopolitical instabilityImpact: MediumLikelihood: Medium

    Conflict in Ukraine and the Middle East may disrupt supply chains and energy prices.

    ExposureGlobal sourcingLogisticsMarket volatility
  3. Tariffs and trade dutiesImpact: MediumLikelihood: Low

    The company says tariffs can affect its ability to adjust prices and forecast costs on time.

    Exposure: Imported ingredients and cross-border supply chains.

  4. Foreign exchange volatilityImpact: Medium

    The Swiss subsidiary creates translation and transaction exposure.

    Exposure: Cross-border operations and non-U.S. activity.

Ask Clarifo about Natural Alternatives International, Inc

Accounting

Judgemental items
Revenue recognition and volume rebates

Management estimates future sales to determine rebate accruals, which can materially change net sales.

Impact: Net revenue and gross margin

Quarterly seasonality and order timing

Large customer orders and shipments can move revenue between quarters.

Impact: Comparability of quarterly results

Foreign currency translation

The Swiss subsidiary is translated into U.S. dollars and can create gains or losses.

Impact: Reported earnings and equity

Publicly listed companies with a comparable business focus.

Last updated: 24/09/2026

Natural Alternatives International, Inc (Nasdaq) – Medicinal Chemicals & Botanical Products | Financial Analysis – Clarifo